Y-mAbs Therapeutics (YMAB) Q1 2025 earnings summary

Executive summary

• Net product revenues reached $20.9 million in Q1 2025, up 8% year-over-year, driven by strong ex-U.S. DANYELZA sales and new commercial programs, offsetting a 28% decline in U.S. sales.

• Business realignment in January 2025 created two units: DANYELZA and Radiopharmaceuticals, aiming to maximize product potential, optimize operations, and accelerate R&D, including a workforce reduction of up to 13%.

• First patient dosed in Phase 1 CD38-SADA trial for relapsed/refractory non-Hodgkin's lymphoma; pivotal and exploratory trials ongoing in multiple indications.

• NCCN updated guidelines to include DANYELZA as a Category 2A treatment for high-risk neuroblastoma, expected to boost U.S. growth.

• Cash and cash equivalents stood at $60.3 million as of March 31, 2025, supporting operations into 2027.

Financial highlights

• Ex-U.S. DANYELZA revenues surged to $7.5 million, up 816% from $0.8 million in Q1 2024, driven by the Named Patient Program and growth in Asia and Latin America.

• U.S. DANYELZA revenues were $13.4 million, down 28% year-over-year, due to slower new patient enrollments and customer ordering patterns.

• Gross profit was $17.9 million, with gross margin at 86% (down from 89% in Q1 2024) due to higher ex-U.S. sales at lower margins.

• Net loss for Q1 2025 was $5.2 million ($0.12 per share), improved from a $6.6 million loss ($0.15 per share) in Q1 2024, mainly due to higher revenues and favorable FX.

• Research and development expenses decreased to $11.4 million, while SG&A expenses increased to $13.1 million, reflecting business realignment and higher personnel costs.

Outlook and guidance

• Reiterated full-year 2025 total revenue guidance of $75–$90 million and expects to fund operations into 2027.

• Q2 2025 revenue guidance set at $17–$19 million, reflecting seasonality and absence of prior year stock-ins.

• DANYELZA pivotal confirmatory trial (Study 201) expected to complete in 2028; additional studies ongoing in osteosarcoma, breast cancer, and Ewing sarcoma.

• Manufacturing transition for DANYELZA to Italy in 2026 may temporarily disrupt supply and increase costs.

• Total operating costs and expenses (including COGS) projected at $129–$134 million for 2025; annual cash investment expected at $25–$30 million.